Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer, Amer M. Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P. Bystrom, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss, Daniel J. DeAngelo, Donna S. Neuberg, Richard M. Stone, Sylvain Garciaz, Brian Ball, Maximilian Stahl

doi:HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27366

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

Authors: Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer, Amer M. Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P. Bystrom, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Stein, Vinod Pullarkat, Ibrahim Aldoss, Daniel J. DeAngelo, Donna S. Neuberg, Richard M. Stone, Sylvain Garciaz, Brian Ball, Maximilian Stahl

Published: 2024-05-16

DOI: HTTPS://DOI.ORG/https://doi.org/10.1002/ajh.27366

Keywords: No keywords found.

Abstract:
No abstract found.

Source:

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study